Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of ...

Attaching "fake targets" to tumor cells to guide immune cell attacks could overcome the limitations of conventional ...

It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

Two teams of researchers have developed a cell reprogramming technology that converts rogue disease-causing T cells from our ...

Producers face decisions that could mean the difference between manageable losses and significant mortalities.

Obstetrician-Gynaecologist, Professor Samuel Antwi Oppong, has explained that while ovarian cancer is one of the most ...

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of ...

Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...